Xun Hu

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Alterations of plasma neural-derived extracellular vesicles microRNAs in patients with bipolar disorder.

Alterations of plasma neural-derived extracellular vesicles microRNAs in patients with bipolar disorder.

Journal: Psychological medicine
Published: August 29, 2025

Unraveling NEK4 as a Potential Drug Target in Schizophrenia and Bipolar I Disorder: A Proteomic and Genomic Approach.

Unraveling NEK4 as a Potential Drug Target in Schizophrenia and Bipolar I Disorder: A Proteomic and Genomic Approach.

Journal: Schizophrenia bulletin
Published: June 13, 2024

Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia.

Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia.

Journal: CNS neuroscience & therapeutics
Published: July 15, 2023

Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk.

Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk.

Journal: Psychological medicine
Published: April 24, 2023

Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.

Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.

Journal: Current neuropharmacology
Published: July 19, 2022

Fingolimod ameliorates schizophrenia-like cognitive impairments induced by phencyclidine in male rats.

Fingolimod ameliorates schizophrenia-like cognitive impairments induced by phencyclidine in male rats.

Journal: British journal of pharmacology
Published: January 29, 2022

Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene.

Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene.

Journal: BMC medicine
Published: November 10, 2021

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial - CORRIGENDUM.

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial - CORRIGENDUM.

Journal: BJPsych open
Published: August 20, 2021

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.

Journal: BJPsych open
Published: October 22, 2020

A plasma metabolomics study suggests alteration of multiple metabolic pathways in patients with bipolar disorder.

A plasma metabolomics study suggests alteration of multiple metabolic pathways in patients with bipolar disorder.

Journal: Psychiatry research
Published: September 10, 2020

Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia.

Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia.

Journal: Neuroscience bulletin
Published: May 08, 2019

Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.

Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.

Journal: The Journal of clinical psychiatry
Published: February 12, 2019
Showing 1-12 of 27

Last Updated: 09/26/2026